Cas No.: | 58493-49-5 |
Chemical Name: | 9-Octadecenamide,N-[(4-hydroxy-3-methoxyphenyl)methyl]-, (9Z)- |
Synonyms: | 9-Octadecenamide,N-[(4-hydroxy-3-methoxyphenyl)methyl]-, (9Z)-;(Z)-N-[(4-hydroxy-3-methoxyphenyl)methyl]octadec-9-enamide;Olvanil;N-vanillylamide;N-vanillyloleamide;N-Vannilyloleoylamide;oleoyl vanillylamide;(N-Vanillyl)-9-oleamide |
SMILES: | CCCCCCCCC/C=C\CCCCCCCC(NCC1=CC(OC)=C(O)C=C1)=O |
Formula: | C26H43NO3 |
M.Wt: | 417.62452 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Description: | Olvanil (NE-19550)is an agonist of transient receptor potential vanilloid type 1 (TRPV1) channels with an EC50 of 0.7 nM.Analgesic[1]. |
Target: | TRPV1:0.7 nM (EC50) |
In Vivo: | Olvanil is one capsaicin analog, which acts as an agonist at the vanilloid receptor. Olvanil may have causes an anxiogenic-like effect. Doses of 0, 0.2, 1.0 and 5.0 mg/kg Olvanil, respectively, yielded percent open arm entries at 5 min of 25±10.1, 19.3±7.1, 14.9±5.9 and 0±0[3]. Animal Model: Sprague-Dawley rats weighing approximately 200 g[3] Dosage: 0, 0.2, 1.0 and 5.0 mg/kg Administration: Injected intraperitoneally 30 min before the behavioral tests Result: The percent open arm times at 5 min were 12.9±8.1 for the 0 mg/kg dose, 8.9±4.2 for the 0.2 mg/kg dose, 15.2±7.9 for the 1 mg/kg dose and 0±0 for the 5 mg/kg dose. The mean number of entries into the closed arm at 5 min were 1.7±0.3, 3.3±0.8, 2.7±0.3 and 0.25±0.1 for doses of 0, 0.2, 1 and 5 mg/kg, respectively. |
In Vitro: | Olvanil affects C6 glioma cell proliferation (IC50 value of 5.5 μM)[2] |
References: | [1]. Giovanni Appendino, et al. Development of the first ultra-potent "capsaicinoid" agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic potential. J Pharmacol Exp Ther. 2005 Feb;312(2):561-70. [2]. S O Jacobsson, et al. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors.J Pharmacol Exp Ther. 2001 Dec;299(3):951-9. [3]. John W Kasckow, et al. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):291-5. |